Biocon provides update on its joint biosimilars development program with Mylan

Presents Phase 3 study Transtuzumab Biosimilar Data at the ASCO Annual Meeting

Biocon announced that the Company along with Mylan presented data from the HERITAGE study at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, 3-7 June. The Phase 3 clinical study confirmed the efficacy, safety and immunogenicity of MYL -14010, the proposed biosimilar trastuzumab co-developed by Biocon and Mylan, in comparision to branded trastuzumab. Trastuzumab is indicated for treatment of HER2-Positive metastatic breast cancer patients.

Powered by Capital Market - Live News